Raytheon awarded $71 million in Navy contracts for missile systems
TORONTO - NetraMark Holdings Inc. (CSE:AIAI) (OTCQB:AINMF), whose stock has surged 34% over the past year according to InvestingPro data, announced Tuesday the appointment of Jan Sedway, Ph.D., as Senior Vice President of Clinical Science as the artificial intelligence company expands its pharmaceutical industry presence.
Dr. Sedway brings over 20 years of leadership experience in clinical research and global operations. She most recently served as Vice President of Clinical Development at Clario, where she led scientific innovation efforts and developed capabilities across therapeutic areas including dermatology and hematology.
Prior to Clario, Dr. Sedway held leadership positions at Parexel and Syneos Health. She holds a Bachelor of Arts in Psychology from the University of Michigan and received her Master of Arts and Doctorate in Psychology from the University of North Carolina at Chapel Hill.
"Her depth of expertise in clinical innovation and operational execution directly aligns with our growth strategy as we continue to drive adoption of our AI-powered solutions," said Josh Spiegel, President of NetraMark, in a press release statement. The company maintains strong financial health with liquid assets exceeding short-term obligations, though InvestingPro analysis indicates it is not currently profitable.
NetraMark focuses on developing generative artificial intelligence and machine learning solutions for the pharmaceutical industry. The company’s technology uses topology-based algorithms to analyze patient data sets, which it claims allows for working with smaller datasets while accurately segmenting diseases and classifying patients for drug sensitivity or treatment efficacy.
The company stated it aims to scale its offerings across psychiatry, oncology and other therapeutic areas as it seeks to capture market share in the expanding AI-driven clinical trial optimization sector. Trading at high revenue and price-to-book multiples, the stock has shown significant momentum with a 14% gain year-to-date. Discover more insights and 8 additional ProTips with an InvestingPro subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.